Event Title
GV-1 Chemical Derivatives as Potential New Antibiotics
Presentation Type
Poster/Portfolio
Presenter Major(s)
Biology
Mentor Information
Rod Morgan, morganr@gvsu.edu
Department
Biology
Location
Henry Hall Atrium 54
Start Date
13-4-2011 9:00 AM
End Date
13-4-2011 10:00 AM
Keywords
Health, Illness, and Healing
Abstract
Despite advancements in many areas of human medicine, infectious disease continues to be a leading cause of morbidity and mortality worldwide. Improper and excessive use of antibacterial compounds has led to the rise of resistant species of bacteria like Methicillin Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococci (VRE), and Extreme Drug Resistant Tuberculosis (XDR-TB). We have found a possible alternative that would replace the current ineffective treatment methods – a potentially new class of antibiotics that inhibits Gram-positive bacteria growth. These chemical compounds have shown inhibition against S. aureus and E. faecalis, and so MRSA and VRE strains were then tested. Inhibition by the newly developed compounds was identical to their inhibition levels against non-resistant strains of both species. These carboxylic amide compounds are novel, non-Penicillin based antibiotics, and could be used to treat MRSA and other Gram-positive infections.
GV-1 Chemical Derivatives as Potential New Antibiotics
Henry Hall Atrium 54
Despite advancements in many areas of human medicine, infectious disease continues to be a leading cause of morbidity and mortality worldwide. Improper and excessive use of antibacterial compounds has led to the rise of resistant species of bacteria like Methicillin Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococci (VRE), and Extreme Drug Resistant Tuberculosis (XDR-TB). We have found a possible alternative that would replace the current ineffective treatment methods – a potentially new class of antibiotics that inhibits Gram-positive bacteria growth. These chemical compounds have shown inhibition against S. aureus and E. faecalis, and so MRSA and VRE strains were then tested. Inhibition by the newly developed compounds was identical to their inhibition levels against non-resistant strains of both species. These carboxylic amide compounds are novel, non-Penicillin based antibiotics, and could be used to treat MRSA and other Gram-positive infections.